ph-0245
print Print Back Back

Zarxio (filgrastim-sndz)

Policy Number: PH-0245

 

(Subcutaneous/Intravenous)

Document Number: IC-0245

Last Review Date: 09/05/2018 

Date of Origin: 03/31/2015

Dates Reviewed: 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017, 08/2017, 11/2017, 02/2018, 05/2018, 09/2018

 

  1. Length of Authorization

Coverage will be provided for six months and may be renewed.  

  1. Dosing Limits
  1. Quantity Limit (max daily dose) [Pharmacy Benefit]:
  • Zarxio 300 mcg prefilled syringe: 3 syringes per 1 day
  • Zarxio 480 mcg prefilled syringe: 3 syringes per 1 day
  1. Max Units (per dose and over time) [Medical Benefit]:

- Severe Chronic Neutropenia:

      • 1380 billable units per day
  • BMT or PBPC:
      • 1200 billable units per day
  • All other indications:
      • 600 billable units per day
  1. Initial Approval Criteria

The patient has another FDA labeled or guideline supported (at highest level of evidence) indication.

Coverage is provided for the following conditions:

Bone marrow transplant (BMT) †

Peripheral Blood Progenitor Cell (PBPC) mobilization and transplant †

Prophylactic use in patients with non-myeloid malignancy †

  • Patient is undergoing myelosuppressive chemotherapy and/or radiotherapy with an expected incidence of febrile neutropenia of 20% or greater§; OR
  • Patient is undergoing myelosuppressive chemotherapy with an expected incidence of febrile neutropenia of 10% or greater§ AND one or more of the following co-morbidities:
  • Elderly patients (age 65 or older) receiving full dose intensity chemotherapy
  • History of recurrent febrile neutropenia from chemotherapy
  • Extensive prior exposure to chemotherapy
  • Previous exposure of pelvis, or other areas of large amounts of bone marrow, to radiation
  • Pre-existing neutropenia (ANC ≤ 1000/mm3)  or bone marrow involvement with tumor
  • Patient has a condition that can potentially increase the risk of serious infection (i.e. HIV/AIDS)
  • Infection/open wounds
  • Recent surgery
  • Poor performance status
  • Poor renal function (creatinine clearance <50)
  • Liver dysfunction (elevated bilirubin >2.0)
  • Chronic immunosuppression in the post-transplant setting including organ transplant

Treatment of chemotherapy-induced febrile neutropenia ‡

  • Used for the treatment of chemotherapy induced febrile neutropenia; AND
    • Patient has been on prophylactic therapy with filgrastim; OR
    • Patient has not received prophylactic therapy with a granulocyte colony stimulating factor; AND
            • Patient has one or more of the following risk factors for developing infection-related complications:
      • Sepsis Syndrome
      • Age >65
      • Absolute neutrophil count [ANC] <100/mcL
      • Duration of neutropenia expected to be greater than 10 days
      • Pneumonia or other clinically documented infections
      • Invasive fungal infection
      • Hospitalization at the time of fever
      • Prior episode of febrile neutropenia

Patient who experienced a neutropenic complication from a prior cycle of the same chemotherapy

Acute Myeloid Leukemia (AML) patient following induction or consolidation chemotherapy †

Bone Marrow Transplantation (BMT) failure or Engraftment Delay

Severe chronic neutropenia †

  • Patient must have an absolute neutrophil count (ANC) < 500/mm3; AND
  • Patient must have a diagnosis of one of the following:
    • Congenital neutropenia; OR
    • Cyclic neutropenia; OR
    • Idiopathic neutropenia
       

Myelodysplastic Syndromes (MDS)

  • Endogenous serum erythropoietin level of ≤500 mUnits/mL; AND
  • Patient is receiving concurrent therapy with Erythropoiesis Stimulating Agents (ESAs)  
     

Patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome) ‡

FDA-labeled indication(s); Compendia recommended indication(s)

§ expected incidence of febrile neutropenia percentages for myelosuppressive chemotherapy regimens can be found in the NCCN Myeloid Growth Factors Clinical Practice Guideline at NCCN.org.

  1. Renewal Criteria

Same as initial prior authorization policy criteria.

  1. Dosage/Administration

Indication

Dose

Zarxio

  • 10 mcg/kg daily for up to 14 days for BMT/PBPC/Radiation indications
  • 6 mcg/kg twice daily for congenital neutropenia
  • 5 mcg/kg daily for up to 14 days for all other indications
  1. Billing Code/Availability Information

JCode:

  • Q5101 – Injection, filgrastim-sndz, biosimilar, (Zarxio), 1 microgram: 1 billable unit = 1 microgram 

NDC:

  • Zarxio 300 mcg prefilled syringe: 61314-0318-xx
  • Zarxio 480 mcg prefilled syringe: 61314-0326-xx
  1. References
  1. Zarxio [package insert]. Princeton, NJ; Sandoz Inc; December 2017. Accessed July 2018.
  2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) filgrastim-sndz. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Compendium, go online to NCCN.org.  Accessed July 2018.
  3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Myeloid Growth Factors. Version 1.2018.  National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Compendium, go online to NCCN.org.  Accessed July 2018.
  4. Kelaidi C Beyne-Rauzy O, Braun T, et al. High Response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol 2013; 92:621-631.
  5. First Coast Service Options, Inc.  Local Coverage Determination (LCD):  G-CSF (Neupogen®, Granix™, Zarxio™) (L34002).  Centers for Medicare & Medicaid Services, Inc.  Updated on 4/25/2018 with effective date 4/1/2018.  Accessed July 2018.
  6. National Government Services, Inc. Local Coverage Article: Filgrastim, Pegfilgrastim, Tbo-filgrastim, Filgrastim-sndz (e.g., Neupogen®, Neulasta™, Granix™, Zarxio™) - Related to LCD L33394 (A52408).  Centers for Medicare & Medicaid Services, Inc.  Updated on 7/06/2018 with effective date 7/15/2018.  Accessed July 2018.
  7. Wisconsin Physicians Service Insurance Corporation. Local Coverage Determination (LCD): Human Granulocyte/Macrophage Colony Stimulating Factors (L34699).  Centers for Medicare & Medicaid Services, Inc.  Updated on 4/20/2018 with effective date 05/1/2018.  Accessed July 2018.
  8. Palmetto GBA. Local Coverage Determination (LCD): White Cell Colony Stimulating Factors (L37176). Centers for Medicare & Medicaid Services, Inc.  Updated on 5/4/2018 with effective date 4/1/2018.  Accessed July 2018.

Appendix 1 – Covered Diagnosis Codes

ICD-10

ICD-10 Description

C92.00

Myeloid leukemia not having achieved remission

C92.02

Myeloid leukemia in relapse

C92.50

Acute myelomonocytic leukemia not having achieved remission

C92.52

Acute myelomonocytic leukemia in relapse

C92.60

Acute myeloid leukemia with 11q23-abnormality not having achieved remission

C92.62

Acute myeloid leukemia with 11q23-abnormality in relapse

C92.A0

Acute myeloid leukemia with multilineage dysplasia not having achieved remission

C92.A2

Acute myeloid leukemia with multilineage dysplasia in relapse

C93.00

Acute monoblastic/monocytic leukemia not having achieved remission

C93.02

Acute monoblastic/monocytic leukemia in relapse

C93.10

Chronic myelomonocytic leukemia, not having achieved remission

C94.00

Acute erythroid leukemia not having achieved remission

C94.02

Acute erythroid leukemia in relapse

C94.20

Acute megakaryoblastic leukemia not having achieved remission

C94.22

Acute megakaryoblastic leukemia in relapse

D46.0

Refractory anemia without ring sideroblasts, so stated

D46.1

Refractory anemia with ring sideroblasts

D46.20

Refractory anemia with excess of blasts, unspecified

D46.21

Refractory anemia with excess of blasts 1

D46.4

Refractory anemia, unspecified

D46.9

Myelodysplastic syndrome, unspecified

D46.A

Refractory cytopenia with multilineage dysplasia

D46.B

Refractory cytopenia with multilineage dysplasia and ring sideroblasts

D46.Z

Other myelodysplastic syndromes

D70.0

Congenital agranulocytosis

D70.1

Agranulocytosis secondary to cancer chemotherapy

D70.2

Other drug-induced agranulocytosis

D70.4

Cyclic neutropenia

D70.9

Neutropenia, unspecified

T45.1X5A

Adverse effect of antineoplastic and immunosuppressive drugs initial encounter

T45.1X5D

Adverse effect of antineoplastic and immunosuppressive drugs subsequent encounter

T45.1X5S

Adverse effect of antineoplastic and immunosuppressive drugs sequela

T66.XXXA

Radiation sickness, unspecified, initial encounter

Z41.8

Encounter for other procedures for purposes other than remedying health state

Z48.290

Encounter for aftercare following bone marrow transplant

Z51.11

Encounter for antineoplastic chemotherapy

Z51.12

Encounter for antineoplastic immunotherapy

Z51.89

Encounter for other specified aftercare

Z52.001

Unspecified donor, stem cells

Z52.011

Autologous donor, stem cells

Z52.091

Other blood donor, stem cells

Z94.81

Bone marrow transplant status

Z94.84

Stem cells transplant status

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx. Additional indications may be covered at the discretion of the health plan.

Jurisdiction(s):  N

NCD/LCD Document (s): L34002

https://www.cms.gov/medicare-coverage-database/search/document-id-search-results.aspx?DocID=L34002&bc=gAAAAAAAAAAA&

Jurisdiction(s):6, K

NCD/LCD Document (s): A52408

https://www.cms.gov/medicare-coverage-database/search/document-id-search-results.aspx?DocID=A52408&bc=gAAAAAAAAAAA&

Jurisdiction(s):  5, 8

NCD/LCD Document (s): L34699

https://www.cms.gov/medicare-coverage-database/search/lcd-date-search.aspx?DocID=L34699&bc=gAAAAAAAAAAA

     

Jurisdiction(s): J, M

NCD/LCD Document (s): L37176

https://www.cms.gov/medicare-coverage-database/search/lcd-date-search.aspx?DocID=L37176&bc=gAAAAAAAAAAA

Medicare Part B Administrative Contractor (MAC) Jurisdictions

Jurisdiction

Applicable State/US Territory

Contractor

E (1)

CA, HI, NV, AS, GU, CNMI

Noridian Healthcare Solutions, LLC

F (2 & 3)

AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ

Noridian Healthcare Solutions, LLC

5

KS, NE, IA, MO

Wisconsin Physicians Service Insurance Corp (WPS)

6

MN, WI, IL

National Government Services, Inc. (NGS)

H (4 & 7)

LA, AR, MS, TX, OK, CO, NM

Novitas Solutions, Inc.

8

MI, IN

Wisconsin Physicians Service Insurance Corp (WPS)

N (9)

FL, PR, VI

First Coast Service Options, Inc.

J (10)

TN, GA, AL

Palmetto GBA, LLC

M (11)

NC, SC, WV, VA (excluding below)

Palmetto GBA, LLC

L (12)

DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)

Novitas Solutions, Inc.

K (13 & 14)

NY, CT, MA, RI, VT, ME, NH

National Government Services, Inc. (NGS)

15

KY, OH

CGS Administrators, LLC